Gilead Sciences announced significant research findings to be presented at the European Association for the Study of the Liver (EASL) Congress in 2024.

Primary Biliary Cholangitis (PBC)

• Long-term data from the Phase 3 ASSURE study will demonstrate the sustained effectiveness and safety of seladelpar for treating PBC.
• The study includes individuals who received a second year of seladelpar after participating in the RESPONSE study.
• Seladelpar targets biochemical responses (e.g., reduced liver enzymes) and pruritus (itching) in PBC patients.

Hepatitis Delta Virus (HDV)

• Gilead will present data from the Phase 2b MYR204 study, showing the efficacy of bulevirtide with or without PegIFN in HDV-infected individuals.
• The Phase 3 MYR301 study, which assesses the effectiveness and safety of bulevirtide as a monotherapy for HDV, will be unveiled.

Hepatitis C Virus (HCV)

• To support the WHO’s goal of eliminating HCV as a public health threat, Gilead will present real-world data and launch a national awareness program in Italy.
• The “Epatite C Mettiamoci un Punto” campaign aims to raise awareness and encourage HCV testing through the “Love Your Liver” Campaign.

Gilead’s research encompasses viral and inflammatory liver diseases, underscoring its dedication to improving patient outcomes and raising awareness.

Source link:

author avatar
Ferry Darma
Ferry Darma is Director of Media Relations at The Clinical Trial Vanguard. Ferry, a computer data scientist, focuses on the latest clinical trial industry news and trends.